Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Checkpoint Blockade Moves Needle in Molecularly Driven Endometrial Cancer Paradigm

November 4th 2021

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

November 3rd 2021

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

November 2nd 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

The Future Management of Cervical Cancer: Novel Agents and Clinical Pearls for Community Onclogists

November 1st 2021

Rounding out her discussion on the use of tisotumab vedotin in cervical cancer, Rebecca Arend, MD, MPH, considers other agents being investigated and how that may impact the future treatment landscape.

FDA Approval of Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

November 1st 2021

A brief review of the FDA approval and implications of tisotumab vedotin in patients with recurrent or metastatic cervical cancer.

Interim Results of the InnovaTV 205 Trial in Cervical Cancer

November 1st 2021

Considerations for the interim results of innovaTV 205, which tested tisotumab vedotin alone or in combination with other agents for patients with cervical cancer.

InnovaTV 204 Trial in Cervical Cancer: Study Design and Key Efficacy Results

November 1st 2021

Rebecca Arend, MD, MPH, reviews the study design and results from innovaTV 204, which tested tisotumab vedotin in previously treated, recurrent, or metastatic cervical cancer.

Evolving Therapy in Cervical Cancer: Tisotumab Vedotin’s Mechanism of Action

November 1st 2021

A historical perspective on the management of recurrent or metastatic cervical cancer, followed by expert insight on tisotumab vedotin’s mechanism of action.

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

October 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended

October 29th 2021

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.

Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

October 28th 2021

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer

October 27th 2021

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

October 27th 2021

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

What is the Current Role of Biomarker Testing in Cervical Cancer?

October 27th 2021

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer

October 22nd 2021

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

October 20th 2021

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Understanding the Biology and Staging of Cervical Cancer

October 20th 2021

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Inguinofemoral Radiotherapy Represents Safe Alternative to Lymphadenectomy in Vulvar Cancer With Micrometastases

October 18th 2021

Inguinofemoral radiotherapy could potentially spare patients with vulvar cancer and sentinel node micrometastases from the morbidity of a lymphadenectomy.

FDA Approves Pembrolizumab Plus Chemo With or Without Bevacizumab for Frontline Cervical Cancer

October 13th 2021

The FDA has approved pembrolizumab for use in combination with chemotherapy, with or without bevacizumab, in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher, as determined by an FDA-approved test.